This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steigerwald-Mullen, P.
Right arrow Articles by Braciale, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steigerwald-Mullen, P.
Right arrow Articles by Braciale, T. J.

 Previous Article  |  Next Article 

Journal of Virology, August 2000, p. 6748-6759, Vol. 74, No. 15
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Type 2 Cytokines Predominate in the Human CD4+ T-Lymphocyte Response to Epstein-Barr Virus Nuclear Antigen 1

Patricia Steigerwald-Mullen,1,2 Michael G. Kurilla,1,2,3 and Thomas J. Braciale1,2,3,*

Beirne B. Carter Center for Immunology Research1 and Departments of Pathology2 and Microbiology,3 University of Virginia Health Sciences Center, Charlottesville, Virginia 22908

Received 15 December 1999/Accepted 3 May 2000


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that persistently infects 85% of the adult population worldwide. In this report, we examine the proliferative response and cytokine secretion profile of CD4+ T lymphocytes from a panel of unrelated EBV-positive donors against two EBV latent antigens, EBNA1 and EBNA3C. Substantial proliferative responses by CD4+ lymphocytes were demonstrated to both antigens in multiple, randomly selected donors. Surprisingly, we observed a striking and consistent difference in cytokine response to EBNA1 and EBNA3C. EBNA1-specific CD4+ T lymphocytes from multiple unrelated donors preferentially produced type 2-like cytokines in response to antigenic stimulation, while the response to EBNA3C was a characteristic type 1 response. The implications of these findings for EBV persistence and the development of EBV-associated malignancies are discussed.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that infects more than 85% of the adult population worldwide and establishes a persistent infection for the lifetime of the host. The EBV carrier state (latency) is characterized by expression of a limited set of EBV genes and by sporadic reactivation of the lytic cycle in latently infected cells, leading to viral replication. Several lines of evidence implicate latently infected B lymphocytes as the major EBV reservoir. Upon reactivation in tonsillar B lymphocytes, EBV can productively infect oropharyngeal epithelium, resulting in infectious virus production and transmission (29, 49).

The importance of EBV as a human pathogen is evinced by its etiologic role in the infectious mononucleosis syndrome. The potential significance of EBV in malignancy is suggested by its B-cell-transforming ability in vitro and by its strong association with a number of human malignancies, including Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, and immunoblastic lymphomas in immunocompromised patients. Despite the oncogenic potential of the virus, the vast majority of EBV-infected individuals remain asymptomatic. A considerable amount of evidence suggests that cell-mediated immune response, particularly CD8+ cytotoxic T-lymphocyte (CTL) recognition of the EBV latent proteins in persistently infected cells, is critical in suppressing EBV replication in latently infected individuals (reviewed in references 49 and 50).

Studies of EBV latent gene expression in persistently infected cells and EBV-positive tumors including both spontaneous and induced EBV-transformed B-lymphoblastoid cell lines (LCL) suggest that up to eight EBV proteins including six nuclear antigens (i.e., EBV nuclear antigen 1 [EBNA1], -2, -3A, -3B, -3C, and -LP) and two membrane proteins (latent membrane protein 1 [LMP1] and 2 [LMP2]) may be differentially expressed in cells exhibiting various forms of EBV latency. Significantly, EBNA1 is the only EBV latent antigen consistently expressed in all patterns of EBV latent gene expression, including EBV-positive malignancies; this reflects its essential function in maintaining the viral genome on latently infected cells. However, the dominant major histocompatibility complex (MHC) class I-restricted CTL responses identified in latently infected EBV carriers are directed to the EBNA3 family of latent gene products. Subdominant reactivities to LMP1 and LMP2, as well as to EBNA2 and EBNALP, have also been found in several individuals (50). By contrast, with rare exceptions (9), MHC class I-restricted CTL responses have not been detected against EBNA1 in EBV-seropositive carriers in spite of the requirement for EBNA1 expression during latent infection. The likely mechanism responsible for this absence of MHC class I-restricted CTL responses against EBNA1 in latently infected cells is cis-acting interference with proteosomal processing of EBNA1 mediated by the internal glycine-alanine repeat domain of EBNA1 (32, 33, 55). This finding led to speculation that inhibition by EBNA1 of its presentation to CD8+ MHC class I-restricted T lymphocytes may account for the lack of elimination of latently infected B lymphocytes in healthy carriers, and hence for EBV persistence and latent infection in healthy carriers (26, 30, 35, 42).

In contrast to the large body of data on the response of MHC class I-restricted CD8+ T lymphocytes to EBV latent proteins, minimal data are available on the response of MHC class II-restricted CD4+ T lymphocytes to these EBV gene products. In view of the importance of EBNA1 in EBV latency and persistence and the lack of a significant MHC class I-restricted CD8+ T-cell response to this latent antigen, we examined the response of CD4+ T lymphocytes to this essential EBV antigen to establish the contribution of EBNA1-specific MHC class II-restricted T lymphocytes to the control of EBV latency. In parallel with the analysis of EBNA1-specific T lymphocytes, we simultaneously examined the response of peripheral blood mononuclear cells (PBMC) from EBV-positive donors to another EBV latent antigen, EBNA3C. In contrast to EBNA1, the EBNA3C antigen represents a dominant target of the vigorous EBV-specific MHC class I-restricted cytolytic CD8+ T-cell response detected in healthy viral carriers (10, 26, 42, 50, 51).

In this report, we demonstrate that EBNA1-specific CD4+ T lymphocytes from the peripheral blood of a panel of unrelated healthy donors mount a vigorous proliferative response and preferentially secrete type 2 cytokines in response to the EBNA1 antigen. By contrast, EBNA3C-specific CD4+ T lymphocytes from these donors exhibit a characteristic type 1 cytokine response to this antigen. The significance of this unique cytokine response to EBNA1 for the maintenance of EBV latency and the development of EBV-related malignancies is discussed.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Subject selection. Blood samples were collected from randomly selected, healthy adults, including three (MK, TB, and CH) with a history of infectious mononucleosis, for isolation of PBMC by Ficoll-Hypaque (Ficoll-Plus [Pharmacia] or Histopaque 1077 [Sigma]) density gradient centrifugation. For donors MK and TB, EBV seropositivity was confirmed by immunoblotting. In some experiments, the buffy coat fractions of blood units obtained from Virginia Blood Services were used as an additional unselected source of PBMC from individuals likely to be EBV infected (in this instance, the lack of donor confidentiality arrangements prevented us from obtaining serum samples for direct confirmation of donor EBV status). PBMC isolated from buffy coats were individually aliquoted and cryopreserved in liquid N2 until needed as a source of responding lymphocytes and/or autologous antigen-presenting cells (APC). All HLA typing for MHC class II alleles was performed by DNA typing through the generous efforts of Mary Carrington (National Cancer Institute, Frederick, Md.) and Karen Siegrist (Clinical Laboratory, University of Virginia [UVA]). Because of the high frequency of EBV seropositivity in the general adult population, cord blood samples isolated from neonatal donors, obtained through the UVA Obstetrics Department, were used to represent EBV-seronegative subjects in initial assays.

EBV preparation. EBV-transformed LCL were generated from individual donors by exogenous virus transformation of PBMC with the prototype EBV isolate B95.8 (63, 64) following established protocols (65). Briefly, approximately 10 × 106 PBMC were cultured at a density of 106/ml in standard RPMI culture medium (RPMI 1640, 2 mM glutamine, 100 IU of penicillin/ml, 100 µg of streptomycin/ml, 10% fetal bovine serum) supplemented with 0.5 µg of cyclosporin A/ml following infection with B95.8-containing supernatants. Cultures were maintained at 37°C and 5% CO2 with weekly (fresh medium) feedings until evidence of transformation. Thereafter, established EBV-transformed LCL were cultured in standard RPMI medium or unsupplemented commercial serum-free medium designed for lymphocytes (AIM-V; Gibco, Gaithersburg, Md.).

Production and purification of eukaryotic (baculovirus-derived) EBNA1. Toxicity of full-length EBNA1 containing a large-interval Gly-Ala repeat sequence limits the expression of this antigen in both eukaryotic and prokaryotic expression systems. To overcome this limitation for eukaryotic expression of EBNA1 in insect cells, an EBNA1 deletion mutant (E1GA [Fig. 1]) lacking the Gly-Ala repeat was constructed by PCR deletional mutagenesis as described elsewhere (9). The E1GA deletion construct was fused with glutathione S-transferase (GST), introduced into a recombinant baculovirus produced in the laboratory of R. Ambinder (Johns Hopkins University), and expressed in SF9 cells. Lysates of baculovirus GST-E1GA and GST control recombinant-expressing insect cells, obtained from Kemp Biotechnologies (Frederick, Md.), were clarified by centrifugation and incubated with glutathione-Sepharose beads (Pharmacia, Piscataway, N.J.) at 4°C on a rotator overnight. Resin containing bound protein was then loaded into a column, washed extensively with sterile phosphate-buffered saline until the wash optical density at 280 nm (OD280) was <= 0.010, and eluted as described below for bacterially expressed GST fusion proteins.


View larger version (29K):
[in this window]
[in a new window]
  		FIG. 1.   (A) Schematic diagram illustrating the recombinant EBNA1 (top) and EBNA3C (bottom) constructs used in this study (see Materials and Methods). Because of technical limitations in the expression of EBNA1 in prokaryotic systems, the E1GA deletion mutant was expressed as a baculoviral recombinant in insect cells. The EBNA1, E1NX, and E1AB constructs are expressed as GST fusion proteins in a prokaryotic expression systems as is the EBNA3C construct, E3C:AAP. (B) SDS-PAGE of recombinant antigen purification. Lysates of insect cells expressing recombinant EBNA1 antigen E1GA as a fusion protein with a GST through a baculovirus vector (lane A) were purified over a glutathione-Sepharose column. Unbound proteins (lane B) were washed away, and purified E1GA antigen (lane C) was eluted as described in Materials and Methods. Purified preparations of control GST protein (lane GST), prokaryote-expressed EBNA1 antigen (lane E1NX), and EBNA3C antigen (lane EBNA3C) were purified in a similar manner. Protein samples were analyzed by Coomassie blue staining of SDS-10% polyacrylamide gels. Positions of molecular weight standards in kilodaltons are indicated on the left. (C) Western blot analysis of purified recombinant antigens. Purified recombinant antigens were analyzed by immunoblot staining of SDS-10% polyacrylamide gels with a human polyclonal antiserum with established reactivity against EBV antigens including EBNA1 and EBNA3C at a 1:200 dilution according to standard protocol. From left to right, the lanes represent prokaryotically expressed GST control antigen (GST), EBNA1 antigens purified from prokaryotes as GST fusion proteins (E1NX and E1AB), EBNA3C antigen expressed as GST fusion protein in prokaryotes (EBNA3C), GST control antigen purified from insect cells (GST), and EBNA1 antigen purified from insect cells as a GST fusion protein (E1GA). Positions of molecular weight standards in kilodaltons are indicated on the far left.

Production and purification of prokaryotic EBNA1 and EBNA3C. The truncated EBNA1 construct (E1NX [Fig. 1]) was made by digesting pBS:E1, containing full-length EBNA1 (5), with NcoI and XcmI, repairing the ends with T4 polymerase (New England Biolabs, Beverly, Mass.), and religating the vector to itself. This resulted in a 379-amino-acid (aa) deletion encompassing the Gly-Ala repeat domain and flanking sequences. The E1NX fragment was excised from the pBS vector using RsaI and inserted into the SmaI site of the pGEX3x (Pharmacia) bacterial fusion protein expression vector. This resulted in an in-frame fusion of GST with EBNA1 starting at EBNA1 aa 8, extending to aa 40, and concluding with aa 420 to 641, the C terminus of EBNA1. The resulting GST-E1NX fusion protein has a predicted molecular mass of 49.8 kDa. In a similar manner, the pGEX:E1AB (Fig. 1) deletion mutant was constructed by PCR amplification of the EBNA1 sequence corresponding to aa 1 to 93, using the EBNA1 N-terminal forward (5'-GAATCATGTCTGACGAGGGGCCAG-3') and reverse (5'-ACCTCCTGCTCCTGTTCCACGGTG-3') primers that had been used in the previous generation of the E1GA deletion mutant (32). The resulting E1AB PCR fragment was cloned into the SmaI site of the pGEX:2T bacterial GST fusion protein expression vector, producing an in-frame fusion of GST with E1AB (EBNA1 aa 1 to 93) with a predicted molecular mass of 36.1 kDa.

To enable efficient prokaryotic expression, plasmid pBS:EBNA3C, containing the coding sequence for full-length EBNA3C (992 aa), was cleaved by a panel of restriction enzymes into a series of smaller fragments. AccI/PstI restriction enzyme digestion of pBS:EBNA3C produced a fragment of EBNA3C encoding aa 376 to 668, designated E3C:AP. Subsequent restriction enzyme digestion and ligation of an oligonucleotide stop codon linker at the AatII site (aa 544) in E3C:AP generated the E3C:AAP construct. After EBNA3C fragment isolation and end repair with T4 DNA polymerase, EBNA3C constructs were inserted into the SmaI site of pGEX3x, resulting in in-frame fusions of GST with the EBNA3C constructs starting at the amino acid positions noted above.

Escherichia coli strain DH10B was transformed with each of the truncated pGEX EBNA1 and EBNA3C fusion constructs (see above) by electroporation, and clones containing inserts in the proper orientation were isolated and confirmed by appropriate restriction enzyme digestion. These were then electroporated into E. coli strain BL21 to increase yields of recombinant protein in some cases. As a control for the fusion tag, pGEX parent vectors without any EBV gene insert were also electroporated into BL21 for purification of GST in parallel with recombinant EBNA1 and EBNA3C. Expression of appropriately sized proteins upon isopropyl-beta -D-thiogalactopyranoside (IPTG) induction of several BL21 clones was confirmed by Coomassie blue staining and immunoblotting after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% gel (27).

For preparative purposes, 100- to 200-ml cultures of rich medium plus ampicillin were inoculated with recombinant EBNA1 and EBNA3C or control pMal and pGEX BL21 clones, allowed to grow to an OD550 of ~0.5, and induced with 0.1 mM IPTG at 37°C for 3 h. Because plasmid loss may occur more readily in liquid culture, particularly for recombinant proteins with bacterial toxicity, clones from glycerol stocks were grown under ampicillin selection on a bacterial plate, the entire contents of which were used to inoculate liquid cultures, thus minimizing the time required for growth before induction.

Bacterial lysates containing protease inhibitors (10 to 20 ml of lysis buffer [1 mg of lysozyme/ml, 50 mM Tris, 100 mM NaCl, 10 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride {pH 8.0 to 8.5}]) were clarified by centrifugation at 38,000 × g and 4°C for 30 min and purified over glutathione-resin (Pharmacia) columns. Column construction, protein binding, column washes, and protein elution followed the manufacturer's protocols except for minor modifications. Columns were washed extensively with phosphate-buffered for glutathione-resin until the wash flowthrough OD280 was <0.010. Recombinant antigens were eluted with approximately 10 ml of elution buffer (10 mM glutathione, 150 mM NaCl, 30 mM HEPES) collected in 1-ml fractions. Fractions containing protein, as determined by the Bradford protein assay, were pooled and quantitated by Bradford assay and SDS-PAGE (10% gel) analysis. Columns were stored and regenerated according to the manufacturer's recommendations.

Lymphocyte culture and the generation of polyclonal CD4+ T-lymphocyte effectors. Polyclonal CD4+ T-lymphocyte effectors specific for EBNA1 or EBNA3C were generated from PBMC following stimulation with the indicated concentration of exogenous recombinant EBNA1 or EBNA3C (see below). PBMC from EBV-positive donors were stimulated with exogenous EBNA1 or EBNA3C at a density of 8 × 106 to 10 × 106/ml and then cultured in 24-well tissue culture plates (Falcon) at 2 × 106 to 2.5 × 106/ml in 2 ml of AIM-V (Gibco) without any supplementation at 37°C and 5% CO2 for 10 to 14 days. The cultures were replenished with fresh AIM-V as necessary (usually 1 week postinitiation).

The EBNA1- and EBNA3C-specific cultures were stimulated every 10 to 14 days with autologous, irradiated PBMC pulsed with the indicated concentration of recombinant EBNA1 or EBNA3C (4 to 12 h of incubation). Responding cells were stimulated at a density of 0.5 × 106 to 1 × 106/well with irradiated APC (1 × 106 to 1.5 × 106/well) in 24-well plates containing 2 ml of AIM-V supplemented with 50 U of human recombinant interleukin-2 (IL-2; Chiron, Emeryville, Calif.) per ml and 20% (vol/vol) supernatants from the MLA-144 cell line (47). Approximately every 4 to 5 days (twice per round of stimulation), the lines were fed with fresh AIM-V supplemented with IL-2 and MLA-144 supernatants. Antigen specificity of the cultures has been ensured by periodic short-term proliferation assays and cytokine assays (see below).

Proliferative responses of bulk PBMC cultures. PBMC were isolated from heparinized blood samples or buffy coats by Ficoll-Hypaque density centrifugation (see above). PBMC were seeded into 96-well plates (2 × 105/well) in AIM-V (Gibco). (A preliminary comparison with RPMI medium [Gibco] supplemented with 10% autologous human or fetal bovine serum demonstrated improved results for the serum-free AIM-V through decreased background proliferation.) Serial dilutions of antigen were added to the wells in triplicate, and triplicate wells containing equimolar concentrations of GST fusion tag were included as a control. Wells containing PBMC alone in media provide the measure of background proliferation used to determine stimulation indices (SI), and phytohemagglutinin (PHA) was used for the positive control. The cultures were incubated at 37°C and 5% CO2 for 5 to 6 days, with the addition of [3H]thymidine (1 µCi/well) on days 4 to 5, and then harvested onto glass fiber filters. Incorporated [3H]thymidine, an indicator of cell proliferation, was assayed with a Packard 9600 direct beta counter or with a model 1205 Betaplate beta counter (Wallace Inc., Gaithersburg, Md.). Results of proliferation assays with bulk PBMC were expressed as SI (ratio of counts per minute of experimental values/background counts per minute), and a specific proliferative response significantly above background (SI >3) was considered significant. Results of proliferation assays with antigen-specific responder cells derived from in vitro stimulation with recombinant EBV antigens were expressed as tritium incorporation in counts per minute (see below).

EBNA1- and EBNA3C-stimulated PBMC cultures (see above) undergoing multiple rounds of in vitro stimulation were periodically assayed in standard proliferation assays to confirm antigen specificity. Approximately 4 days after feeding with IL-2, responding T cells from these cultures (1 × 2 × 104/well) were cultured in triplicate in 96-well round-bottom plates in AIM-V at 37°C and 5% CO2 with 105 autologous, irradiated APC (LCL or PBMC) that had been preincubated with antigen. Control groups containing no antigen, no responders, or no APC served as negative controls, while cultures stimulated with PHA were included as positive controls. Cells were pulsed with [3H]thymidine (1 µCi/well) at 48 h for 16 h and subsequently harvested as described above.

Determination of MHC restriction by inhibition of proliferation with monoclonal antibodies. MHC restriction of the proliferative responses was analyzed by inhibiting proliferative responses with appropriate monoclonal antibodies according to established protocols (20a, 59a). Briefly, inhibitory anti-class I (W6/32) or anti-HLA-DP (PL15), anti-HLA-DQ (193F10), and anti-HLA-DR (PL8) monoclonal antibodies (provided by J. Sung, UVA) were preincubated with bulk peripheral blood lymphocytes (PBL) (or irradiated APC) corresponding to a final concentration of 5 to 25 µg/ml 0.5 h before pulsing with antigen (and adding responder cells). Cultures were incubated and pulsed with [3H]thymidine according to the proliferation assay protocol described above, and significant (>= 80%) decreases in the resulting proliferative responses were attributed to the particular MHC restrictions.

Analysis of EBNA1- and EBNA3C-specific cytokine secretion. Cytokine assays were performed by establishing replicate cultures of responder cells (0.25 × 106 to 0.5 × 106/ml) with APC (autologous LCL or irradiated autologous PBMC; 0.25 × 106 to 0.5 × 106/ml) that had been preincubated with the indicated concentration of recombinant EBV antigen or GST control from 4 to 16 h. Cytokine assay cultures were incubated in tissue culture plates (usually 96-well plates with 0.225 ml of medium/well) in AIM-V without supplementation at 37°C and 5% CO2 for 24 h. The cells were then pelleted, and supernatants were harvested and stored at -80°C until assayed for cytokine production using commercial enzyme-linked immunosorbent assay (ELISA)-based kits. Cytokine assays were established with EBNA1- or EBNA3C-specific responders at the indicated day poststimulation (usually days 7 to 10 after the third round of stimulation). In some cases, supernatants were periodically collected from EBNA1- and EBNA3C-specific responder cultures at the indicated times poststimulation and assayed for cytokine production by ELISA.

Cytokine production was determined by analyzing culture supernatants for the production of gamma interferon (IFN-gamma ; Endogen), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-4, IL-13, and IL-5 (Pharmingen, San Diego, Calif.), using commercial reagents according to the ELISA protocol recommended by the manufacturer. Results are expressed as the average concentration of cytokine in the supernatant samples from replicate cultures. The sensitivity of the assays in the range of 0.010 to 0.020 ng/ml.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Proliferative responses to EBNA1 and EBNA3C. Recombinant EBNA1 and EBNA3C constructs (Fig. 1A; see Materials and Methods) were used as the antigen source for in vitro induction of memory T-lymphocyte responses in PBMC from healthy adult viral carriers. Results of analyses of the recombinant EBV proteins by SDS-PAGE (Fig. 1B) and Western blotting (Fig. 1C) are shown. An EBNA1 construct representing the unique coding regions of this antigen (aa 1 to 92 and 326 to 641) was expressed in a baculovirus expression system as an in-frame fusion with a GST tag for subsequent purification. To achieve efficient expression of EBNA3C, the coding sequence of the 991-aa gene product was divided into a series of smaller fragments individually expressed as GST fusion proteins in a prokaryotic expression system. The EBNA3C construct selected for this investigation, E3CAAP (aa 376 to 668), represents a region which produced optimal EBNA3C-specific proliferative responses in preliminary screening with PBMC from several EBV carriers (data not shown). Limited analysis with overlapping synthetic peptides has indicated that this region of EBNA3C contains multiple epitopes recognized in association with an array of MHC class II alleles (P. Steigerwald-Mullen, unpublished observations).

Figure 2 shows the proliferative response to EBNA1 and EBNA3C of PBMC from two unrelated donors of different HLA type. Lymphocytes from both donors proliferated in response to both antigens in a dose-dependent fashion (Fig. 2). The EBV antigen specificity is indicated by the absence of significant response (i.e., SI >= 3) from these PBMC populations to equimolar concentrations of GST fusion tag controls (from parental GST expression vectors lacking EBV gene inserts which were induced and purified in parallel with the EBV recombinant GST-antigen fusion products). In companion assays (Fig. 3), proliferative responses of PBMC from donor MK to both EBNA1 and EBNA3C were found to be inhibited (>80%) by addition of monoclonal antibodies directed to human MHC class II molecules but not by antibodies to MHC class I molecules, indicating that donor MHC class II-restricted CD4+ T lymphocytes were proliferating in response to the soluble EBV latent protein antigens.


View larger version (22K):
[in this window]
[in a new window]
  		FIG. 2.   Representative ex vivo proliferation assays illustrating EBNA1- and EBNA3C-specific memory responses of PBMC from two EBV-positive donors, MK and donor BC1. PBL (2 × 105/well) were cultured in triplicate with the indicated concentrations of recombinant EBNA1 (E1GA) (top panels) or EBNA3C (E3C:AAP) (bottom panels) GST fusion proteins in standard 5-day proliferation assays as described in Materials and Methods. Equimolar concentrations of the GST fusion tags with no EBV gene inserts served as a control. Results are expressed as SI.


View larger version (22K):
[in this window]
[in a new window]
  		FIG. 3.   MHC class II restriction of EBNA1- and EBNA3C-proliferative responses. EBNA1 (top)- and EBNA3C (bottom)-specific responders from donor MK were assayed in standard 3-day proliferation assays against irradiated autologous APC that had been preincubated with E1GA or E3C:AAP antigen (black bars) or control GST protein (open bars) in the presence of blocking antibodies (10 µg/ml, final concentration) specific for either HLA-DP (PL15), HLA-DQ (193F10), or HLA-DR (PL8) as detailed in Materials and Methods.

As described below (see Table 1), significant EBNA1- and EBNA3C-specific proliferative responses were observed with PBMC from multiple unrelated individuals. This observation is in keeping with the high frequency of latent EBV infection (>85%) in the human population (49). These results along with the high incidence of immunoglobulin G antibody to EBNA1 and the easily inducible CD8+ T-lymphocyte response to EBNA3 in the peripheral blood of EBV-infected individuals (29, 49, 50) suggest that the EBNA1- and EBNA3C-specific proliferation and cytokine production described in this report most likely reflects the in vitro response of CD4+ memory T lymphocytes to these soluble EBV latent proteins. To further ensure that the vigorous proliferation response of PBL (particularly to EBNA1) was not due to a mitogenic or superantigen-like property of this protein, we examined the response of lymphocytes from three EBV-negative donors (i.e., umbilical cord derived PBMC from three neonates). As Fig. 4 demonstrates, all three lymphocyte sources mounted a vigorous response to stimulation with the mitogen PHA, but the PBMC failed to mount a response to EBNA1 over a range of concentrations. By contrast, the EBV-seropositive lymphocyte donor, MK, mounted a vigorous proliferative response to both EBNA1 and the mitogen PHA (Fig. 4). Both the EBV specificity and substantial magnitude of EBNA1- and EBNA3C-specific responses in EBV-positive donors strongly suggest that these latent antigens are reactivating memory (or recall) T-lymphocyte responses from PBMC of healthy, persistently infected EBV carriers.


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 4.   EBV specificity of proliferative responses to EBNA1. PBL from EBV-seropositive donor MK and three EBV-seronegative neonatal donors (PBL derived from cord blood samples) were assayed against the indicated concentrations of EBNA1 antigen in standard 5-day proliferation assays as detailed in Materials and Methods. The EBNA1 antigen fails to elicit a significant response in PBL from EBV-negative donors, although these PBL readily proliferated in response to PHA stimulation (SI of 35, 66, and 49, respectively).

Divergent effector phenotypes and cytokine profiles of EBNA1- and EBNA3C-specific responses. Having established that EBNA1- and EBNA3C-specific memory CD4+ T lymphocyte responses are reactivated from PBMC of EBV-positive donors using exogenous recombinant antigens, we analyzed the cytokine profile of the effector T lymphocytes responding to these antigens to gain insight into the regulatory roles of these populations in EBV immunity. Accordingly, EBNA1- and EBNA3C-specific responses from a panel of three unrelated EBV-positive donors were initially assayed for the secretion of the cytokines IFN-gamma (type 1), IL-4 (type 2), and IL-5 (type 2), representative of the cytokine profiles of type 1 and type 2 CD4+ T-cell subsets, respectively. Because of technical limitations with IL-4 detection by ELISA in initial studies, an analysis of IL-13 production in response to EBNA1 and EBNA3C was performed as a surrogate for the type 2-associated cytokine IL-4, since IL-13 has similar effects as IL-4 and is reportedly secreted in parallel with IL-4 (15, 67). In subsequent assays, GM-CSF production was quantitated in parallel with the prototype type 1 and type 2 cytokines IFN-gamma and IL-5 as an indicator of overall lymphocyte responsiveness since GM-CSF secretion has been reported to be independent of type 1 or type 2 polarization of effector T lymphocytes (34, 62).

Representative cytokine responses of EBNA1- and EBNA3C- specific lymphocyte cultures, established from PBMC of three unrelated EBV-positive donors, are shown in Fig. 5. A striking difference was observed in the cytokine profiles of reactivated memory T lymphocytes responsive to EBNA1 and EBNA3C in the three donors. Despite donor-to-donor variability in the quantity of cytokine secretion, CD4+ T lymphocytes from all donors produced the type 2-associated cytokines, IL-5 and IL-13, as well as IFN-gamma in response to EBNA1. This contrasts with the type 1-type cytokine profile displayed for EBNA3C-specific responses, as evident by IFN-gamma secretion by EBNA3C-specific T lymphocytes and the absence of significant levels of IL-5 and/or IL-13 (Fig. 5). These data are representative of three or more independent experiments using PBMC from these donor samples over a 6- to 18-month period. The comparable levels of IFN-gamma (and GM-CSF [see below]) secretion as well as the similar magnitude of proliferative responses (Fig. 2) exhibited by EBNA1- and EBNA3C-specific lymphocytes for each donor suggest comparable levels of T-lymphocyte stimulation by the two antigens. These findings argue against a difference in antigen potency or memory cell frequency as the cause of the distinctly different cytokine profiles of EBNA1- and EBNA3C-specific T lymphocytes.


View larger version (17K):
[in this window]
[in a new window]
  		FIG. 5.   Representative cytokine responses of EBNA1- and EBNA3C-specific T-lymphocyte cultures established from three unrelated EBV-positive donors, MK, TB, and BC1, illustrating the differences in cytokine effector profiles between EBNA1- and EBNA3C-specific effectors. PBL were cultured with recombinant EBNA1 and EBNA3C antigens in parallel, and equivalent numbers of EBNA1- or EBNA3C-specific effectors were assayed for the indicated cytokine after the fourth in vitro stimulation with antigen as detailed in Materials and Methods. IFN-gamma , IL-5, and IL-13 production was measured by ELISA from culture supernatants of EBNA1- and EBNA3C-specific effectors assayed in triplicate at 24 h after stimulation with antigen. The donor HLA-DR and DQ haplotypes are listed in Table 1.

Maturation of CD4+ effector cytokine profiles in vitro. Figure 6 illustrates the time course of cytokine secretion in supernatants of lymphocyte cultures established from PBMC of EBV-positive donor MK following successive rounds of stimulation with EBNA1 or EBNA3C antigen. Production of the type 2 cytokine IL-5 by the EBNA1-specific T lymphocytes was detected only after several rounds of in vitro stimulation with the EBNA1 antigen. IL-5 production by EBNA1-stimulated cultures was reproducibly observed only after three rounds of in vitro stimulation with this antigen. In contrast, the response to EBNA3C was characterized by a type 1-type cytokine secretion profile throughout multiple rounds of in vitro restimulation with EBNA3C antigen. It is important to note that GM-CSF and IFN-gamma were produced by PBMC cultures stimulated with either EBNA1 or EBNA3C during the first round of in vitro antigenic stimulation, and production of these cytokines was stably maintained for EBNA3C-specific cultures through multiple rounds of in vitro stimulation. It should also be noted that even though the production of IFN-gamma by EBNA3C-specific T cells during the second round of in vitro stimulation was reproducibly lower than the IFN-gamma response during the third round of stimulation, the level of IFN-gamma production (i.e., 2 to 3 ng/ml) was still substantial. Furthermore, with progressive expansion of these EBNA3C-specific cells after several rounds of restimulation, significant IL-5 production was not detected.


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 6.   Maturation of cytokine effector phenotype over successive exposures to antigen. PBMC from EBV-positive donor MK were cultured with 0.25 µM EBNA1 or EBNA3C as described in Materials and Methods. Equivalent numbers of EBNA1 (left)- or EBNA3C (right)-specific T lymphocytes were serially stimulated in vitro three times with irradiated autologous PBL pulsed with 0.25 µM antigen. Following each successive stimulation, GM-CSF, IFN-gamma , and IL-5 levels were determined by ELISA in 72-h culture supernatants.

The finding that EBNA1-specific T lymphocytes (like EBNA3C-specific T lymphocytes) produced GM-CSF and IFN-gamma after one round of in vitro antigenic stimulation and sustained the production of these two cytokines at increasing levels after successive rounds of restimulation in vitro is also noteworthy. This result along with the finding of vigorous and comparable proliferative responses to EBNA1 and EBNA3C (Fig. 2) suggests that EBNA1-specific T lymphocytes are present at a high frequency in EBV carriers and are comparably responsive over successive rounds of antigenic stimulation. Thus, the requirement for multiple rounds of in vitro stimulation with EBNA1 for type 2 (i.e., IL-5) cytokine expression most likely reflects a maturation of the type 2 cytokine-producing effector cell phenotype among EBNA1-specific T lymphocytes in response to antigen rather than the progressive expansion during in vitro stimulation of EBNA1-specific CD4+ T lymphocytes initially present at a low frequency in peripheral blood.

Antigen dose influences the magnitude of cytokine production but not the cytokine profile of EBV latent antigen-specific T lymphocytes. Antigen dose has been reported to influence the type 1/type 2 polarization of effector responses derived from naive lymphocyte precursors (reviewed in reference 12). However, the effect of antigen dose on the type of cytokines produced by activated effectors in response to antigenic stimulation is not well defined (12). It was therefore of interest to determine whether the dose of EBNA1 or EBNA3C used to elicit cytokine production from activated effector T lymphocytes (i.e., following several rounds of in vitro antigenic stimulation) influenced the type 1/type 2 polarization of these cells. To address this issue, we analyzed the cytokine response of activated effector T lymphocytes to a range of EBNA1 or EBNA3C doses.

Figure 7 depicts representative dose-response curves from such an analysis for two unrelated donors. Cytokine production by EBNA1- or EBNA3C-specific activated (effector) lymphocytes derived from donor MK and BC6 PBMC was determined using autologous LCL pulsed with EBNA1 or EBNA3C over a range of antigen concentrations. The activated lymphocytes harvested and analyzed 5 days after the third round of in vitro stimulation with homologous antigen (see Materials and Methods). While the magnitude of cytokine response to EBNA1- or EBNA3C-pulsed LCL varied in a dose-dependent manner, the cytokine profile of the EBNA1- or EBNA3C-specific effector T cells was not effected by the antigen dose used to elicit cytokine secretion from the activated T cells. Both EBNA1- and EBNA3C-specific effector lymphocytes responded in an antigen-dose dependent fashion and demonstrated comparable antigen responsiveness, as indicated by the magnitude of IFN-gamma and GM-CSF production. Importantly, IL-5 production by EBNA1-specific effectors was directly proportional to the antigen dose used to elicit the response. Thus, the selective production of IL-5 by EBNA1-specific CD4+ T-lymphocyte effectors was quantitatively but not qualitatively altered by the dose of antigen used in vitro to elicit cytokine production. It is noteworthy that the distinct type 2 and type 1 cytokine profiles, displayed by EBNA1- and EBNA3C-specific effectors, respectively, were observed at the same antigen dose (0.25 µM) used for in vitro stimulation (i.e., reactivation) of memory lymphocytes. In addition, the absence of a significant cytokine response by EBNA1-specific effector T lymphocytes to either the GST fusion tag control antigen or the irrelevant EBNA3C antigen confirms the EBNA1 specificity of the differentiated effector cells in vitro.


View larger version (24K):
[in this window]
[in a new window]
  		FIG. 7.   Representative antigen dose-response curves for EBNA1- and EBNA3C-specific effectors from two EBV-positive donors, MK and BC1. Memory T lymphocytes were reactivated from PBL of donors MK and BC1 by in vitro stimulation with 0.25 µM EBNA1 or EBNA3C as described in Materials and Methods. After the third round of in vitro stimulation with antigen, equivalent numbers of EBNA1- or EBNA3C-specific effectors (105 cells/well) were assayed in triplicate for GM-CSF (top), IFN-gamma (middle), and IL-5 (bottom) production 24 h after stimulation with the indicated concentrations of EBNA1 () or EBNA3C (black-triangle). Equivalent concentrations of the GST control protein served as a negative control to confirm antigen specificity (open symbols).

The above analysis suggests that the dose of EBNA1 used to elicit cytokine responses from effector lymphocytes influenced the magnitude of the IL-5 cytokine response but not the commitment of these T effectors to a type 2-like cytokine response. However, since antigen dose could affect the ex vivo differentiation of memory lymphocytes to polarized effectors, it was important to determine if differences in the antigen dose used to activate and restimulate EBNA1-specific memory lymphocytes in vitro could account for the preferential IL-5 production by EBNA1-specific effectors. To address this issue, EBNA1- or EBNA3C-specific memory lymphocytes were activated and restimulated at one of three fixed antigen concentrations corresponding to a 25- to 50-fold range of antigen dose. The effector lymphocytes elicited over these antigen doses were then assayed for cytokine secretion in response to autologous LCL APC pulsed with various concentrations of EBNA1 or EBNA3C. These results, summarized in Fig. 8, indicated that the range of antigen doses capable of generating antigen-specific responses in vitro has minimal effects on the observed type 1/type 2 polarization of effector phenotypes. The magnitude of induction of EBNA1-specific effectors and the concomitant production of cytokines were directly proportional to the dose of antigen used for memory lymphocyte stimulation. However, the type 2 polarization of these effector lymphocytes (i.e., the production of IL-5) was independent of the antigen dose used for in vitro stimulation of memory T lymphocytes. Likewise, EBNA3C-specific effectors generated from memory cells stimulated over a 50-fold range of stimulating antigen concentration demonstrated dose-dependent, antigen-specific GM-CSF and IFN-gamma responses without significant IL-5 production. Analysis of the lymphocyte cell surface phenotype of the responding cells in culture by flow cytometry revealed that >80% of the viable cells in culture at the time of cytokine elicitation with the EBV antigens were CD4+ (data not shown).


View larger version (29K):
[in this window]
[in a new window]
  		FIG. 8.   Antigen dose dependence of in vitro induction of memory EBNA1- and EBNA3C-specific cytokine responses. Various doses of the EBNA1 or EBNA3C were used to activate and restimulate memory T lymphocytes. PBMC from donor MK were stimulated in vitro with one of three fixed doses of EBNA1 or EBNA3C corresponding to a 25- to 50-fold range of antigen and restimulated with the same antigen dose to generate activated EBNA1- and EBNA3C-specific effectors (see Materials and Methods). The resulting EBNA1- or EBNA3C-specific effectors were then assayed for cytokine secretion 24 h after stimulation with the indicated dose of EBNA1 or EBNA3C antigen (x axis). IFN-gamma and IL-5 production by T lymphocytes in response to EBNA1 or EBNA3C along with GST controls is shown. GM-CSF responses are omitted for clarity, but they directly paralleled IFN-gamma secretion.

Absence of influences of recombinant antigen expression systems on the resulting effector phenotypes. Since the recombinant EBNA1 and EBNA3C antigens were expressed in eukaryotic and prokaryotic expression systems, respectively, it was important to evaluate the contribution of the antigen source on the cytokine profile of the latent antigen-specific T lymphocytes. For this purpose, recombinant EBNA1 protein was expressed in the prokaryotic GST fusion system used for EBNA3C. Technical limitations (see Materials and Methods) in the expression of the Gly-Ala repeat-deleted EBNA1 antigen in prokaryotes necessitated the use of deletion constructs for expression of prokaryotic EBNA1 (Fig. 1). These prokaryotic EBNA1 constructs, E1AB and E1NX, represent a more limited region of EBNA1 than the constructs expressed in the baculovirus system. Specifically, E1AB encodes EBNA1 aa 1 to 92, and E1NX represents aa 1 to 39 and 420 to 641, as in-frame C-terminal fusions with GST.

Figure 9 illustrates the cytokine responses of EBNA1- or EBNA3C-specific effectors derived from PBMC of three unrelated EBV-positive donors following in vitro stimulation with prokaryotically expressed EBNA1 or EBNA3C antigens. Again, within individual donors, comparable levels of antigen responsiveness of EBNA1- and EBNA3C-specific lymphocytes were indicated by the similar levels of GM-CSF and IFN-gamma secretion. Significant IL-5 production was evident in cultures of EBNA1-stimulated lymphocytes from all three donors when EBNA1 antigen of prokaryotic origin was used. Thus, the dichotomy in CD4+ effector phenotypes between EBNA1- and EBNA3C-specific memory T lymphocytes is independent of the source of EBNA1 antigen.


View larger version (22K):
[in this window]
[in a new window]
  		FIG. 9.   Representative EBNA1- and EBNA3C-specific cytokine responses of PBMC from three unrelated donors, MK (A), BC6 (B), and BC5 (C), after in vitro stimulation with the prokaryote-derived EBNA1 antigen E1NX or E1AB or with the prokaryotic EBNA3C antigen. The response to the eukaryotic (baculovirus) EBNA1 construct (E1GA) was included for donor BC6. After the third round of in vitro stimulation with antigen, equivalent numbers of EBNA1- or EBNA3C-specific effectors were analyzed for IFN-gamma , GM-CSF, and IL-5 production in response to 24-h stimulation. The response to the control GST antigen was at background levels in all instances and is excluded for clarity.

Summary of EBNA1- and EBNA3C-specific effector cytokine responses for an extended donor panel. In view of the striking difference in the cytokine response of EBNA1- and EBNA3C-specific T lymphocytes among several unrelated donors, it was of interest to determine if this difference in cytokine profile was exhibited by a larger panel of donors. We therefore extended this analysis of EBNA1- and EBNA3C-specific CD4+ T-lymphocyte effector responses to include a total of 13 randomly selected individuals. For each PBMC donor, GM-CSF, IFN-gamma , and IL-5 cytokine production by EBNA1- and EBNA3C-specific effector T lymphocytes were assessed after the third round of in vitro antigenic stimulation. Representative results for each donor (along with HLA class II typing where determined) are reported in Table 1. Of the 13 donors evaluated, 10 demonstrated responses to both EBNA1 and EBNA3C. In all cases, only EBNA1-specific T-lymphocyte effectors from these donors secreted significant levels of the type 2 cytokine IL-5. EBNA3C-specific T lymphocytes from these donors exhibited a type 1 pattern with little or no IL-5 production. Comparable results were obtained in two or more independent in vitro analyses using PBMC from donors of known HLA type. Results from three randomly selected donors (BC7, BC9, and BC10), were obtained after a single in vitro analysis of the cytokine response to EBNA1 and EBNA3C.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Cytokine response of EBNA1- and EBNA3C-specific T lymphocytes

Two of the 13 donors (BC2 and BC4) failed to respond to EBNA1 or EBNA3C on two independent occasions. These individuals are most likely EBV negative, but serum samples were not available from these donors to establish EBV seronegativity (see Materials and Methods). The EBNA1-stimulated culture initiated from one donor (BC8 [not shown]) failed to respond after the second round of in vitro stimulation, precluding a comparison of EBNA1- and EBNA3C-specific effector cytokine phenotypes. EBNA3C-specific effector T lymphocytes from this donor did, however, produce significant levels of IFN-gamma and GM-CSF but no IL-5 (not shown).


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

In this report, we have examined the proliferative and cytokine responses of CD4+ memory T lymphocytes from a panel of randomly selected, unrelated EBV-positive donors to two EBV latent antigens, EBNA1 and EBNA3C. Both antigens elicit proliferative T-lymphocyte responses. However, CD4+ memory T lymphocytes to EBNA1 and EBNA3C exhibit distinctly different cytokine profiles after stimulation with antigen in vitro. While EBNA3C-specific T lymphocytes produce a cytokine profile consistent with a type 1-type polarization (i.e., high levels of IFN-gamma and low levels of IL-5 or IL-13), the response of EBNA1-specific T lymphocytes is characterized by production of the prototypic type 2 cytokines IL-5 and IL-13. However, since EBNA1-specific CD4+ T cells produce both the type 2 cytokines IL-5 and IL-13 and the type 1 cytokine IFN-gamma , these responding T cells should be formally classified as Th0-like effector T cells. Importantly, the distinct cytokine secretion profiles of EBNA1- and EBNA3C-specific effectors is independent of donor HLA type and not influenced by the source or dose of antigen used for in vitro reactivation of memory T lymphocytes.

We could routinely demonstrate a vigorous proliferative response to EBNA1 by PBMC from multiple EBV-positive donors ex vivo (Fig. 2 and 5). Since EBNA1-specific proliferative responses were not detected in umbilical cord-derived PBMC (Fig. 4) or in two adult PBMC donors (Table 1), this robust response to EBNA1 is unlikely due to a superantigen or mitogenic effect of EBNA1. However, as we do not have serologic confirmation that the two nonresponding individuals represented in Table 1 were EBV seronegative, the failure of these individuals to respond to EBNA1 or EBNA3C may be due to other reasons. Overall, these findings suggest that there is a high frequency of EBNA1-specific CD4+ memory T lymphocytes circulating in the blood of healthy viral carriers. Therefore, in contrast to the defective presentation of EBNA1 via the MHC class I processing pathway (9, 32, 50), processing and presentation of EBNA1 through the MHC class II presentation pathway is intact in vivo and ex vivo (16, 21, 27, 28, 46).

The secretion of type 2 cytokines by EBNA1-specific T lymphocytes in vitro required repeated exposure to this antigen. These results parallel findings in other systems where the induction of a type 2 cytokine response, particularly IL-5 production, required several rounds of stimulation of memory lymphocytes in vitro by antigen (7, 11, 14, 58). It is, therefore, likely that the circulating EBNA1-specific CD4+ T lymphocytes in the peripheral blood in vivo and those that are responding to EBNA1 antigen in vitro are primed memory cells and not a circulating pool of activated type 2 cytokine-producing effectors. Indeed, the low frequency of B lymphocytes latently infected with EBV (1 in 106 circulating B cells [60]) in healthy carriers is consistent with the expected low probability of isolating activated CD4+ T-lymphocyte effectors producing type 2 cytokines ex vivo from the peripheral blood. Furthermore, the stability of the type 1-type cytokine profile for EBNA3C-specific lymphocytes over an identical in vitro antigen restimulation protocol argues against selective expansion of lymphocytes producing type 2 cytokines because of the particular in vitro culture conditions used herein, or because of a preferential susceptibility of type 1 cytokine-secreting CD4+ T lymphocytes to activation-induced cell death (11, 65, 66), as the explanation for the preferential Th0 cytokine response to EBNA1.

Although EBNA1- and EBNA3C-specific T lymphocytes differed in the capacity to secrete type 2 cytokines in response to antigen, they produced comparable amounts of IFN-gamma in response to antigen. The IFN-gamma production by EBNA1-specific T-cell populations directly paralleled the production of GM-CSF and was not inversely proportional to IL-5 production. This suggests that the IFN-gamma production was related to the frequency of antigen-responsive memory T lymphocytes and was independent of type 2 cytokine production. Similar analyses of CD4+ T-lymphocyte responses to antigens in both humans and mice have, likewise, not found a reciprocal relationship between IFN-gamma production and the production of type 2-type cytokines by antigen-specific T lymphocytes (25, 52, 53, 56, 58, 59).

The type 1/type 2 polarization of CD4+ T-lymphocyte responses against viral antigens has been suggested to play a significant role in the virus-mediated regulation of the host responses to experimental murine, as well as some human, viral infections. For example, disease progression in human immunodeficiency virus infection (2, 17), susceptibility to recurrent herpes simplex labialis episodes (57), and the development of chronic hepatitis B (36-38) and hepatitis C (48, 63) virus infections have all been reported to be associated with the development of type 2-like responses and/or a reduction in proinflammatory type 1-like responses. Similarly, in several experimental murine viral infections, the development of a type 1 response during infection is associated with viral clearance, while the development of type 2 responses or the administration of type 2 cytokines delays viral clearance and exacerbates disease (8, 24, 40, 41, 45). However, demonstration of the selective inductions of a type 2 response to particular viral antigens has been mainly limited to experimental infections in the murine model (37, 38, 45, 58, 59). To our knowledge, this is the first demonstration of the selective induction of differentially polarized cytokine responses by memory T cells to a specific viral antigen in an unselected human population after natural infection.

The mechanism(s) underlying the preferential triggering of a polarized cytokine response by EBNA-specific memory T lymphocytes is unknown. A number of factors, including antigen dose, epitope selection, antigen persistence, and cytokine milieu, have been implicated in regulating CD4+ T-lymphocyte differentiation and the preferential production of type 1 or type 2 cytokine responses (reviewed in references 1, 12, 41, 43, and 54). Our finding that the polarized cytokine response of EBNA1- or EBNA3C-specific T cells was independent of the antigen dose used for the induction of memory T cells or for the elicitation of cytokine production by effector T lymphocytes argues against regulation of responsiveness at the level of antigen dose. Similarly, the demonstration of preferential Th0/Th2-like cytokine response to EBNA1 by CD4+ T lymphocytes from the majority of randomly selected individuals of various HLA types argues against the selection of type 2-like epitopes by the disparate MHC class II molecules displayed by these individuals as the mechanism for the type 2 cytokine response exhibited by EBNA1-specific T lymphocytes from these donors.

Several unique features of the host response to EBNA1 and/or its role in EBV persistence in vivo could account for the difference in cytokine polarization between the EBNA1-responding T cells and the T cells responding to EBNA3C. First, unlike EBNA3C and other EBV latent antigens, EBNA1 does not elicit a CD8+ CTL response because of its ability to inhibit its own processing and presentation to CD8+ T cells (32, 33). There is evidence from several systems suggesting that the induction of antigen-specific CD8+ T-lymphocyte responses may promote the differentiation of CD4+ T lymphocytes along the type 1 pathway (22, 23, 59). In a similar manner, the induction of CD4+ T-lymphocyte responses by EBNA1 in the absence of a concomitant CD8+ T-lymphocyte response (which is generated in the response to EBNA3C and several other EBV latent antigens [50]) could result in the preferential differentiation of activated EBNA1-specific CD4+ T lymphocytes along the Th0/Th2 pathway. Our preliminary studies to date do not suggest a role for CD8+ T lymphocytes in regulating CD4+ T-lymphocyte differentiation during the differentiation of EBNA1- and EBNA3C-specific memory T lymphocytes into activated effector cells in this in vitro induction system. However, CD8+ T lymphocytes responding to EBV latent antigens could influence the in vivo generation of circulating CD4+ memory T lymphocytes and result in production of EBNA1- or EBNA3C-specific CD4+ memory T lymphocytes precommitted to the type 1 or type 2 differentiation pathway at the time of antigen exposure in vitro.

Alternatively, the differences in the cytokine responses to these two EBV latent antigens may reflect differences in the site or level of expression of these two proteins in latently infected healthy carriers. Available evidence indicates that continuous low-level EBNA1 expression is required for viral genome persistence and that EBNA1-expressing latently infected B lymphocytes are the likely reservoir for EBV in vivo (49, 60). By contrast, EBNA3C expression is down-regulated in B lymphocytes during persistent EBV infection (49, 60). Thus, it is possible that continuous EBNA1 expression in infected individuals mimics the chronic low-dose antigenic stimulation proposed for the type 2 polarization of CD4+ T lymphocytes directed to allergens (12). Whether low-level antigen persistence or the absence of a regulatory CD8+ T-lymphocyte response accounts for the unique character of the CD4+ T-lymphocyte response to EBNA1, our results suggest that EBNA1-specific memory T lymphocytes are precommitted to Th0/Th2 polarization at the time of reexposure to this antigen in vitro.

Because of the apparent qualitative difference in the in vitro response of PBMC from disparate donors to these two EBV latent antigen, it is tempting to speculate on the potential biological significance of the, albeit in vitro, findings reported here. Specifically the production of anti-inflammatory type 2 cytokines by EBNA1-specific CD4+ effector T lymphocytes could contribute to EBV persistence in asymptomatic carriers through downregulation of the host inflammatory/immune response against the latently infected B-lymphocyte reservoir in carriers. This speculation must be tempered, however, for several reasons. First, little or no information is available on the cytokine response of T lymphocytes from asymptomatic carriers responding to other latency-associated EBV proteins (e.g., EBNA2, -3A, -3B, and -LP). It will be necessary to directly demonstrate that these other latent EBV antigens induce, like EBNA3C, a preferential CD4+ type-1 cytokine response in EBV carriers before a unique role of EBNA1 in maintaining EBV persistence in vivo can be validated. Second, as reported here, the CD4+ T-lymphocyte response to EBNA1 includes the production of the proinflammatory cytokine IFN-gamma . The potential interplay of proinflammatory and anti-inflammatory cytokines produced by EBNA1 specific CD4+ T lymphocytes in maintaining EBV persistence is not as yet clear but must be taken into account in considering the role of EBNA1 in regulating EBV persistence and latency in vivo.

In spite of the above caveats and the limitations inherent with in vitro data, the potential contribution of anti-inflammatory cytokines produced by CD4+ T lymphocytes responding to EBNA1 along with the ability of this protein to inhibit CD8+ T-lymphocyte response suggests a novel role for EBNA1 in promoting the escape of latently infected B lymphocytes from immune surveillance. For example, since type 2 cytokines have been reported to promote the growth and survival of EBV-infected B lymphocytes (3-6), a type 2 cytokine response to EBNA1 would also enhance viral persistence by sustaining the in vivo reservoir of latently infected B cells. In contrast, upon reactivation or the expression of the EBV latent antigen EBNA3C, the induction of both a CD8+ CTL response and a proinflammatory CD4+ type 1 cytokine response would result in the elimination of virally infected cells. This response in turn would limit virus replication and suppress the development of potentially lethal EBV-driven lymphoproliferative disease.

Although the pathogenesis of EBV-associated malignancies remains a subject of speculation, individuals with EBV-positive malignancies, such as Hodgkin's lymphoma and Burkitt's lymphoma, have demonstrable EBV-specific immune responses despite an inability to eradicate the tumor (18-20, 28). Indeed, viral and human IL-10 has been implicated in a local suppression of EBV-specific immune recognition of EBV-positive Hodgkin's lymphomas and nasopharyngeal carcinomas (19, 31, 44, 64). In this context, it is noteworthy that many EBV-positive malignancies demonstrate a latency II pattern of EBV gene expression (49), in which latent nuclear antigen expression is restricted to EBNA1, with variable levels of the latent membrane proteins. Although the full spectrum of the host immune response during EBV latency in vivo has not been examined, our observations reinforce the view that there exists a complex and dynamic balance between the viral gene products and the host immune system responding to these gene products which simultaneously promotes EBV persistence and regulates the replication of the transforming virus.


    ACKNOWLEDGMENTS

We thank Shawn Gill for expert editorial support, Barbara Small for excellent technical support, and our colleagues in the Department of Pathology and the Carter Immunology Center for discussions, reagents, and advice.

This work was supported by USPHS grants AI-15608, AI-28317, and AI-37293 (to T.J.B.) and by the UVA Asthma and Allergic Disease Center.


    FOOTNOTES

* Corresponding author. Mailing address: Beirne Carter Center for Immunology Research, P.O. Box 801386, 400 Lane Road, MR-4 Building, Rm. 4012, University of Virginia, Charlottesville, VA 22908. Phone: (804) 924-1219. Fax: (804) 924-1221. E-mail: tjb2r{at}virginia.edu.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383:787-793[CrossRef][Medline].
2. Barker, E., C. E. Mackewicz, and J. A. Levy. 1995. Effects of type 1 and type 2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival. Proc. Natl. Acad. Sci. USA 92:11135-11139[Abstract/Free Full Text].
3. Baumann, M. A., and C. C. Paul. 1997. Interleukin-5 and human B lymphocytes. Methods 11:88-97[CrossRef][Medline].
4. Beatty, P. R., S. M. Krams, and O. M. Martinez. 1997. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J. Immunol. 158:4045-4051[Abstract].
5. Bejarano, M. T., and M. G. Masucci. 1998. Interleukin-10 abrogates the inhibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood 92:4256-4262[Abstract/Free Full Text].
6. Bende, R. J., G. J. Jochems, T. H. Frame, M. R. Klein, R. V. van Eijk, R. A. van Lier, and W. P. Zeijlemaker. 1992. Effects of IL-4, IL-5, and IL-6 on growth and immunoglobulin production of Epstein-Barr virus-infected human B cells. Cell. Immunol. 143:310-323[CrossRef][Medline].
7. Bird, J. J., D. R. Brown, A. C. Mullen, N. H. Moskowitz, M. A. Mahowald, J. R. Sider, T. F. Gajewski, C. R. Wang, and S. L. Reiner. 1998. Helper T cell differentiation is controlled by the cell cycle. Immunity 9:229-237[CrossRef][Medline].
8. Biron, C. A., and R. T. Gazzinelli. 1995. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr. Opin. Immunol. 7:485-496[CrossRef][Medline].
9. Blake, N., S. Lee, I. Redchenko, W. Thomas, N. Steven, A. Leese, P. M. Steigerwald-Mullen, M. G. Kurilla, L. Frappier, and A. Rickinson. 1997. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791-802[CrossRef][Medline].
10. Burrows, S. R., J. Gardner, R. Khanna, T. Steward, J. Moss, S. Rodda, and A. Suhrbier. 1994. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J. Gen. Virol. 75:2489-2493[Abstract/Free Full Text].
11. Carter, L. L., X. Zhang, C. Dubey, P. Rogers, L. Tsui, and S. L. Swain. 1998. Regulation of T cell subsets from naive to memory. J. Immunother. 21:181-187.
12. Constant, S. L., and K. Bottomly. 1997. Induction of type 1 and type 2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15:297-322[CrossRef][Medline].
13. Dambaugh, T., C. Beisel, M. Hummel, W. King, S. Fennewald, A. Cheung, M. Heller, N. Raab-Traub, and E. Kieff. 1980. Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc. Natl. Acad. Sci. USA 77:2999-3003[Abstract/Free Full Text].
14. Demeure, C. E., L. P. Yang, D. G. Byan, H. Ishihara, N. Vezzio, and G. Delespesse. 1995. Human naïve CD4 T cells produce interleukin-4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditions. Eur. J. Immunol. 25:2722[Medline].
15. de Vries, J. E. 1996. Molecular and biological characteristics of interleukin-13. Chem. Immunol. 63:204-218[Medline].
16. Dillner, J., R. Szigeti, W. Henle, G. Henle, R. A. Lerner, and G. Klein. 1987. Cellular and humoral immune responses to synthetic peptides deduced from the amino-acid sequences of Epstein-Barr virus-encoded proteins in EBV-transformed cells. Int. J. Cancer 40:455-460[Medline].
17. DiPiro, J. T. 1997. Cytokine networks with infection: mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. Pharmacotherapy 17:205-223[Medline].
18. Dolcetti, R., and M. Boiocchi. 1998. Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Biomed. Pharmacother. 52:13-25[CrossRef][Medline].
19. Dolcetti, R., T. Frisan, J. Sjoberg, P. O. De Campos-Lima, P. Pisa, V. De Re, A. Gloghini, S. Rizzo, M. G. Masucci, and M. Boiocchi. 1995. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease. Cancer Res. 55:3675-3681[Abstract/Free Full Text].
20. Frisan, T., J. Sjoberg, R. Dolcetti, M. Boiocchi, V. Dere, A. Carbone, C. Brautbar, S. Battat, P. Biberfeld, M. Eckman, O. Ost, B. Christensson, C. Sundstrom, M. Bjorkholm, P. Pisa, and M. G. Masucci. 1995. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86:1493-1501[Abstract/Free Full Text].
20a. Gelder, M. S. 1995. Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection. J. Virol. 69:7497-7506[Abstract].
21. Henle, W., G. Henle, J. Andersson, I. Ernberg, G. Klein, C. A. Horwitz, G. Marklund, L. Rymo, C. Wellinder, and S. E. Straus. 1987. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc. Natl. Acad. Sci. USA 84:570-574[Abstract/Free Full Text].
22. Holmes, B. J., P. A. MacAry, A. Noble, and D. M. Kemeny. 1997. Antigen-specific CD8+ T cells inhibit IgE responses and interleukin-4 production by CD4+ T cells. Eur. J. Immunol. 27:2657-2665[Medline].
23. Hussell, T., C. J. Baldwin, A. O'Garra, and P. J. Openshaw. 1997. CD8+ T cells control type 2-driven pathology during pulmonary respiratory syncytial virus infection. Eur. J. Immunol. 27:3341-3349[Medline].
24. Karupiah, G. 1998. Type 1 and type 2 cytokines in antiviral defense. Vet. Immunol. Immunopathol. 63:105-109[CrossRef][Medline].
25. Kelso, A. 1995. Type 1 and type 2 subsets: paradigms lost? Immunol. Today 16:374-379[CrossRef][Medline].
26. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, V. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-176[Abstract/Free Full Text].
27. Khanna, R., S. R. Burrows, P. M. Steigerwald-Mullens, D. J. Moss, M. J. Kurilla, and L. Cooper. 1997. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int. Immunol. 9:1537-1543[Abstract/Free Full Text].
28. Khanna, R., S. R. Burrows, P. M. Steigerwald-Mullen, S. A. Thomson, M. G. Kurilla, and V. Moss. 1995. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 214:633-637[CrossRef][Medline].
29. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-96. In B. N. Fields, P. M. Howley, and D. M. Knipe (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
30. Kurilla, M. G. 1993. Target antigens of Epstein-Barr virus (EBV) and the implications for immune control of EBV-associated disease. Semin. Virol. 4:95-100.
31. Lee, S. P., C. M. Constandinou, W. A. Thomas, D. Croom-Carter, N. W. Blake, P. G. Murray, J. Crocker, and A. B. Rickinson. 1998. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 92:1020-1030[Abstract/Free Full Text].
32. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688[CrossRef][Medline].
33. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M. G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 94:12616-12621[Abstract/Free Full Text].
34. Markus, N. R., S. A. Rosenberg, and S. L. Topalian. 1995. Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes. J. Interferon Cytokine Res. 15:739-746[Medline].
35. Masucci, M. G., and I. Ernberg. 1994. Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol. 2:125-130[CrossRef][Medline].
36. Milich, D. R. 1997. Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection. J. Viral Hepatitis 4(Suppl. 2):48-59.
37. Milich, D. R., D. L. Peterson, F. Schodel, J. E. Jones, and J. L. Hughes. 1995. Preferential recognition of hepatitis B nucleocapsid antigens by type 1 or type 2 cells is epitope and major histocompatibility complex dependent. J. Virol. 69:2776-2785[Abstract].
38. Milich, D. R., F. Schodel, J. L. Hughes, J. E. Jones, and D. L. Peterson. 1997. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J. Virol. 71:2192-2201[Abstract].
39. Miller, G., and M. Lipman. 1973. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc. Natl. Acad. Sci. USA 70:190-194[Abstract/Free Full Text].
40. Moran, T. M., H. Isobe, A. Fernandez-Sesma, and J. L. Schulman. 1996. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J. Virol. 70:5230-5235[Abstract/Free Full Text].
41. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: type 1, type 2 and more. Immunol. Today 17:138-146[CrossRef][Medline].
42. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157-168[Abstract/Free Full Text].
43. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275-283[CrossRef][Medline].
44. Ohshima, K., J. Suzumiya, M. Akamatu, M. Takeshita, and M. Kikuchi. 1995. Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4+ and CD8+ T lymphocytes. Int. J. Cancer 62:5-10[Medline].
45. Openshaw, P. J. 1995. Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am. J. Respir. Crit. Care Med. 152:S59-S62.
46. Petersen, J., G. Rhodes, K. Patrick, J. Roudier, and J. H. Vaughan. 1989. Human T cell responses to the Epstein-Barr nuclear antigen-1 (EBNA1) as evaluated by synthetic peptides. Cell. Immunol. 123:325-333[CrossRef][Medline].
47. Rabin, H., R. F. Hopkins III, F. W. Ruscetti, R. H. Neubauer, R. L. Brown, and T. G. Kawakami. 1981. Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J. Immunol. 127:1852-1856[Abstract].
48. Reiser, M., C. G. Marousis, D. R. Nelson, G. Lauer, R. P. Gonzalez-Peralta, G. L. Davis, and J. Y. Lau. 1997. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J. Hepatol. 26:471-478[CrossRef][Medline].
49. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-46. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
50. Rickinson, A. B., and D. J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405-431[CrossRef][Medline].
51. Rickinson, A. B., S. P. Lee, and N. M. Steven. 1996. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr. Opin. Immunol. 8:492-497[CrossRef][Medline].
52. Romagnani, S. 1995. Biology of human type 1 and type 2 cells. J. Clin. Immunol. 15:121-129[CrossRef][Medline].
53. Sarawar, S. R., M. Sangster, R. L. Coffman, and P. C. Doherty. 1994. Administration of anti-IFN-gamma antibody to beta 2-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a T helper cell 2 phenotype. J. Immunol. 153:1246-1253[Abstract].
54. Seder, R. A., and W. E. Paul. 1994. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12:635-673[CrossRef][Medline].
55. Sharipo, A., M. Imreh, A. Leonchiks, S. Imreh, and M. G. Masucci. 1998. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4:939-944[CrossRef][Medline].
56. Spender, L. C., T. Hussell, and P. J. Openshaw. 1998. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. J. Gen. Virol. 79:1751-1758[Abstract].
57. Spruance, S. L., T. G. Evans, M. B. McKeough, L. Thai, B. A. Araneo, R. A. Daynes, E. M. Mishkin, and A. S. Abramovitz. 1995. Type 1/type 2-like immunity and resistance to herpes simplex labialis. Antiviral Res. 28:39-55[CrossRef][Medline].
58. Srikiatkhachorn, A., and T. J. Braciale. 1997. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71:678-685[Abstract].
59. Srikiatkhachorn, A., and T. J. Braciale. 1997. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186:421-432[Abstract/Free Full Text].
59a. Steele, J. C., T. Stankovic, and P. H. Gallimore. 1993. Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein. J. Virol. 67:2799-2806[Abstract/Free Full Text].
60. Steven, N. M. 1997. Epstein-Barr virus latent infection in vivo. Rev. Med. Virol. 7:97-106[CrossRef][Medline].
61. Steven, N. M., A. M. Leese, N. E. Annels, S. P. Lee, and A. B. Rickinson. 1996. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J. Exp. Med. 184:1801-1813[Abstract/Free Full Text].
62. Topalian, S. L., L. Rivoltini, M. Mancini, J. Ng, R. J. Hartzman, and S. A. Rosenberg. 1994. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer 58:69-79[Medline].
63. Tsai, S. L., Y. F. Liaw, M. H. Chen, C. Y. Huang, and G. C. Kuo. 1997. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25:449-458[CrossRef][Medline].
64. Yao, M., K. Ohshima, J. Suzumiya, T. Kume, T. Shiroshita, and M. Kikuchi. 1997. Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int. J. Cancer 72:398-402[CrossRef][Medline].
65. Zhang, X., T. Brunner, L. Carter, R. W. Dutton, P. Rogers, L. Bradley, T. Sato, J. C. Reed, D. Green, and S. L. Swain. 1997. Unequal death in T helper cell (Th)1 and type 2 effectors: type 1, but not type 2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 185:1837-1849[Abstract/Free Full Text].
66. Zhang, X., L. Giangreco, H. E. Broome, C. M. Dargan, and S. L. Swain. 1995. Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J. Exp. Med. 182:699-709[Abstract/Free Full Text].
67. Zurawski, G., and J. E. de Vries. 1994. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today 15:19-26[CrossRef][Medline].

Journal of Virology, August 2000, p. 6748-6759, Vol. 74, No. 15
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Bhaduri-McIntosh, S., Rotenberg, M. J., Gardner, B., Robert, M., Miller, G. (2008). Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. Blood 111: 1334-1343 [Abstract] [Full Text]  
  • Tsang, C. W., Lin, X., Gudgeon, N. H., Taylor, G. S., Jia, H., Hui, E. P., Chan, A. T. C., Lin, C. K., Rickinson, A. B. (2006). CD4+ T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived Epitopes.. J. Virol. 80: 8263-8266 [Abstract] [Full Text]  
  • Gudgeon, N. H., Taylor, G. S., Long, H. M., Haigh, T. A., Rickinson, A. B. (2005). Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+ T Cells as the Principal Effectors and a Novel CD4+ T-Cell Reactivity. J. Virol. 79: 5477-5488 [Abstract] [Full Text]  
  • Long, H. M., Haigh, T. A., Gudgeon, N. H., Leen, A. M., Tsang, C.-W., Brooks, J., Landais, E., Houssaint, E., Lee, S. P., Rickinson, A. B., Taylor, G. S. (2005). CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines. J. Virol. 79: 4896-4907 [Abstract] [Full Text]  
  • Nikiforow, S., Bottomly, K., Miller, G., Munz, C. (2003). Cytolytic CD4+-T-Cell Clones Reactive to EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation. J. Virol. 77: 12088-12104 [Abstract] [Full Text]  
  • Precopio, M. L., Sullivan, J. L., Willard, C., Somasundaran, M., Luzuriaga, K. (2003). Differential Kinetics and Specificity of EBV-Specific CD4+ and CD8+ T Cells During Primary Infection. J. Immunol. 170: 2590-2598 [Abstract] [Full Text]  
  • Leen, A., Meij, P., Redchenko, I., Middeldorp, J., Bloemena, E., Rickinson, A., Blake, N. (2001). Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses. J. Virol. 75: 8649-8659 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steigerwald-Mullen, P.
Right arrow Articles by Braciale, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steigerwald-Mullen, P.
Right arrow Articles by Braciale, T. J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»